Amneal's erythromycin tablets launch
Amneal on Tuesday received Food and Drug Administration approval for its erythromycin tablets, immediately launching the product. Amneal said that its generic is the only alternative oral release tablet on the market.
“Amneal is committed to increasing access to affordable medications,” Amneal executive vice president of commercial operations Andy Boyer said. “Erythromycin tablets are a great example of a product with limited availability where we can now provide patients and pharmacists with options.”
Amneal’s tablets are sold in 100-count bottles of 25- and 50-mg dosage strength tablets.
The product had a market size of roughly $84 million in the 12 months ended January 2018, according to IQVIA data.
“Amneal is committed to increasing access to affordable medications,” Amneal executive vice president of commercial operations Andy Boyer said. “Erythromycin tablets are a great example of a product with limited availability where we can now provide patients and pharmacists with options.”
Amneal’s tablets are sold in 100-count bottles of 25- and 50-mg dosage strength tablets.
The product had a market size of roughly $84 million in the 12 months ended January 2018, according to IQVIA data.